Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LATS1 | O95835 | 2/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089199 | 1.00 | NAMPT (0.48) | NAMPTCYP3A4HPGDSHDAC3HDAC1 | |
| SCHEMBL23081593 | 0.85 | HDAC3 (0.42) | NAMPTCYP3A4HPGDSHDAC3HDAC1 | |
| SCHEMBL30525777 | 0.85 | HDAC3 (0.42) | NAMPTCYP3A4HPGDSHDAC3HDAC1 | |
| SCHEMBL19210478 | 0.84 | HPGDS (0.50) | NAMPTHPGDSHDAC3HDAC1HDAC2 | |
| SCHEMBL31625175 | 0.80 | L3MBTL1 (0.43) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL18701559 | 0.80 | KDM4E (0.50) | NAMPTHPGDSHDAC3HDAC1HDAC2 | |
| SCHEMBL4030710 | 0.79 | CYP3A4 (0.48) | CYP3A4L3MBTL1CA12CA1CA2 | |
| SCHEMBL18567056 | 0.79 | STK17B (0.45) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL29611056 | 0.79 | SMN1; SMN2 (0.61) | L3MBTL1KDM4ERAB9A | |
| SCHEMBL4678395 | 0.79 | SMN1; SMN2 (0.61) | L3MBTL1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022246092-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-111936495-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| CN-103813800-B | Active agent prodrugs with heterocyclic linkers | 特色疗法股份有限公司 | 2017-12-19 | — | — | CN | disclosed |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | SIGNATURE THERAPEUTICS INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9139612-B2 | Active agent prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139612-B2 | Active agent prodrugs with heterocyclic linkers | SIGNATURE THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101595110-A | Be used for immunosuppressant 7-substituted purin derivatives | PHARMACOPEIA INC (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-2099800-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | Pharmacopeia, LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| CN-101203516-A | Purine and imidazopyridine derivatives for immunosuppression | PHARMACOPEIA INC (US) | 2008-06-18 | — | — | CN | disclosed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | NAMPT 700/4885CYP3A4 1539/4885HPGDS 283/4885 |
| US-20160002291-A1 | Active Agent Prodrugs with Heterocyclic Linkers | PEPD, SI, PREP | NAMPT 1466/4885CYP3A4 168/4885HPGDS 517/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | NAMPT 118/4885CYP3A4 702/4885HPGDS 130/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | NAMPT 118/4885CYP3A4 702/4885HPGDS 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.